NCT05524935 2026-04-01Olaparib in Combination With Pembrolizumab for Advanced Uveal MelanomaH. Lee Moffitt Cancer Center and Research InstitutePhase 2 Recruiting37 enrolled
NCT05482074 2024-01-19Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2Dana-Farber Cancer InstitutePhase 2 Withdrawn